检索结果-南通市图书馆

Hydroxychloroquine alone or in combination with azithromycin and corrected QT prolongation in COVID-19 patients:A systematic review

引用

World Journal of Meta-Analysis 2021年第6期9卷 557-567页

作者： Haleh Ashraf Parham Ghafouri Sina kazemian Abbas Soleimani Azadeh Sadat Naseri Shahrokh Karbalai ali kazemi saeid Research Development Center Sina HospitalTehran University of Medical SciencesTehran 11367-46911Iran Cardiac Primary Prevention Research Center(CPPRC) Tehran Heart CenterTehran University of Medical SciencesTehran 11367-46911Iran Students'Scientific Research Center(SSRC) Tehran University of Medical SciencesTehran 11367-46911Iran School of medicine Tehran University of Medical ScienceTehran 11367-46911Iran Department of Cardiology Sina HospitalTehran University of Medical SciencesTehran 11367-46911Iran

BACKGROUND Despite the controversies about the effectiveness of the current drug regimens for coronavirus disease 2019(COVID-19),these drugs are still the only options ***,the safety of these drugs is yet to be confirmed.A serious concern is the occurrence of various cardiac arrhythmias,particularly QT *** To summarize the incidence and estimate the risk of QT interval prolongation in patients scheduling for conventional treatment(hydroxychloroquine alone or in combination with azithromycin)for *** We comprehensively searched Medline,Web of Knowledge,Google Scholar,Scopus,and Cochrane Central Register of Controlled Trials databases until October 31,2020 for all eligible studies under the considered keywords COVID19,arrhythmia,QT interval,therapy,azithromycin,and hydroxychloroquine *** study protocols were established in compliance with PRISMA-P guidelines(Preferred Reporting Items for Systematic Review and Meta-Analysis–Protocols),and a nine-star Newcastle-Ottawa Scale scoring system was used to assess the methodological quality of all eligible *** measures were corrected QT(QTc)prolongation,cardiac arrhythmias,or sudden cardiac *** Fifteen studies enrolling 8298 patients with targeted COVID-19 therapeutic regimes were *** eligible studies found a significant increase in the mean QTc interval following treatment with the described medications compared to baseline QTc with weighted standard differences in means of *** pooled prevalence rate of QTc prolongation was estimated to be 9.2%(95%confidence interval:4.5%to 18.1%).CONCLUSION Hydroxychloroquine±azithromycin regimen can significantly increase the risk of developing QTc prolongation.

关键词： Azithromycin COVID-19 Hydroxychloroquine QTc interval

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Troponin I biomarker as a strong prognostic factor for predicting COVID-19 mortality:A systematic review

引用

World Journal of Meta-Analysis 2021年第4期9卷 342-352页

作者： Haleh Ashraf Abbas Soleimani ali kazemi saeid Azadeh Sadat Naseri Fazeleh Majidi Niloufar Peirovi Shahrokh Karbalai Saleh Department of Cardiology Tehran University of Medical SciencesTehran ***Iran Cardiac Primary Prevention Research Center(CPPRC) Cardiovascular Diseases Research InstituteTehran University of Medical SciencesTehranIranzip code *** Reserch and Development Center Sina HospitalTehran University of Medical SciencesTehran ***Iran

BACKGROUND The increase in circulating Troponin-I in the blood of patients suffering coronavirus disease 2019(COVID-19)can be a strong prognostic factor for predicting disease poorer *** To review the literatures to approve this claim *** Two blinded reviewers independently screened the titles and abstracts of the manuscripts using the keywords and deeply searching the databanks including PubMed,Scopus,Google Scholar,and Web of knowledge,followed by profoundly appraisement of the full texts to assess the inclusion *** The manuscripts entered into our final assessment were categorized as the two groups including 10 manuscripts describing and comparing death and diseaserelated complications between the subgroups of patients with raised serum troponin level and those with normal ranges of this biomarker and 7 manuscripts comparing the mean level of serum troponin concentration across the survived and non-survived *** outcome of COVID-19 disease in the groups with raised troponin level and normal level of this markers showed increased the likelihood of death[hazard ratio(HR)=4.967,P<0.001],acute respiratory distress syndrome(HR=5.914,P<0.001),acute kidney injury(HR=3.849,P<0.001),and intensive care unit(ICU)admission(HR=3.780,P<0.001)following raise of *** pooled analysis showed significantly higher concentration of this marker in the survived group compared to non-survived group(weighted mean differences of 22.278,95%CI:15.647 to 28.927,P<0.001).CONCLUSION Raising troponin-I on admission can be linked to the increase risk for in-hospital death,acute respiratory distress syndrome,kidney injury,and ICU admission by 4.9,5.9,3.8,and 3.7 times as compared to those with initial normal troponin-I ***,raising baseline value of troponin-I can be used as a prognostic factor for poor outcome of COVID-19.

关键词： Troponin-I COVID-19 Mortality Morbidity Cardiac biomarker Acute respiratory distress syndrome

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：